KROS Q4 2023 Earnings — Keros Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

KROSKeros Therapeutics, Inc.

$414M

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$143,000

Gross Profit

$143,000100.0% margin

Operating Income

-$46M-32486.0% margin

Net Income

-$40M-28142.0% margin

EPS (Diluted)

$-1.34

QoQ Revenue Growth

+1687.5%

Cash Flow

Operating Cash Flow

-$25M

Free Cash Flow

-$26M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$370M

Total Liabilities

$38M

Stockholders' Equity

$332M

Cash & Equivalents

$331M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$143,000	$0	—
Gross Profit	$143,000	$0	—
Operating Income	-$46M	-$32M	-45.4%
Net Income	-$40M	-$30M	-35.4%